Medical cannabis: Syncann enters the market taking a stand against express consultations
Want to learn more about the ecosystem? Visit Syncann's official website and follow the launch on August 12 in Brazil.
Medical cannabis enters a new chapter in Brazil this August with the official launch of Syncann, scheduled for August 12. Born from the real-life experience of a patient and healthcare professional, the new platform emerges with a clear goal: to counter the logic of "express consultations" and restructure the patient journey through an integrated ecosystem that combines technology, education, and responsible access.
In this article, you will see:
The end of the fragmented journey in cannabinoid treatment
Why the express consultation model threatens healthcare
How Syncann technology simplifies doctors' routines
The Syncann ecosystem: Academy, Connect, and Access
The impact of new Anvisa guidelines on the sector
The End of the Fragmented Journey in Medical Cannabis
Despite the exponential growth of the market in recent years, the search for medical cannabis treatment is still marked by a disconnected journey. The difficulty of finding trained professionals, the lack of continuous monitoring, and uncertainties surrounding product purchases make the process confusing for those seeking quality of life.
It was by experiencing these bottlenecks firsthand — first as a patient in 2019 and later as a healthcare professional — that Syncann's founder envisioned the platform. The main goal is to connect all ends of the ecosystem, ensuring that care does not end the moment a medical prescription is issued.
"Expanding access is fundamental, but access cannot mean giving up quality of care. A consultation is not just a step to obtain a prescription; it is part of a continuous journey."
The Danger of Express Consultations in Clinical Follow-up
One of Syncann's main banners is its critical stance against ultra-fast virtual appointments, which usually last between 15 and 20 minutes. In cannabinoid medicine, where each body responds uniquely to phytocannabinoids, rushed care compromises treatment efficacy.
Responsible care requires the doctor to understand the patient's history, current medications, specific symptoms, and routine. The startup's proposal is precisely to restore listening time and long-term follow-up, ensuring greater patient autonomy and clinical safety for the prescriber.
[LEARN MORE: How does the titration and dosage process work in medical cannabis?]
Technology Serving the Doctor and Alignment with Anvisa
To support this new experience without overloading healthcare professionals, Syncann technology was custom-built for the practice of cannabinoid medicine.
The platform simplifies the doctor's operational work, automating bureaucratic steps and organizing patient medical records. Furthermore, the tools are built to align with the latest regulatory requirements of Anvisa, allowing prescribers to spend less time on paperwork and more time on clinical decision-making.
Discover the 3 Verticals of the Syncann Ecosystem
To deliver a comprehensive solution for patients, prescribers, and industry companies, Syncann is structured around three integrated pillars:
1. Syncann Academy
An educational arm focused on democratizing quality information. It empowers everyone from patients — so they understand their treatment and actively participate in their healthcare — to prescribers and professionals seeking continuous scientific updates on the plant.
2. Syncann Connect
The central platform where patient and doctor meet. It goes far beyond scheduling: offering smart tools for daily monitoring, symptom tracking, and continuous support.
3. Syncann Access
A front dedicated to demystifying access pathways to cannabis-based products, facilitating the understanding of import channels, pharmacies, and associations within legal boundaries.
[LEARN MORE: Anvisa regulations for cannabis products: what changed?]
A New Era for Human and Technological Care
The launch of Syncann on August 12 represents a maturity milestone for the Brazilian market. By proving that technology should serve to humanize medicine — rather than rush it indiscriminately —, the company proposes a model where education, access, and follow-up go hand in hand.
Sources and Bibliographic References:
Agência Nacional de Vigilância Sanitária (ANVISA). Resolutions on RDC and guidelines for importing and prescribing Cannabis-derived products.
Journal of Cannabis Research. Patient-Reported Outcomes and Long-Term Tracking in Cannabinoid Therapy (2024).
Conselho Federal de Medicina (CFM). Medical Ethics Code and Resolutions on Telemedicine and Continuous Care.